Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Albutrepenonacog Alfa
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CSL Behring's IDELVION® Becomes First and Only Factor IX Therapy with 21-Day Prophylactic
Details : EMA has approved the new Summary of Product Characteristics, which includes information about new, extended dosing options for IDELVION® CSL Behring's novel, long-acting recombinant albumin fusion protein for treating haemophilia B.
Brand Name : Idelvion
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 03, 2020
Lead Product(s) : Albutrepenonacog Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?